Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products

被引:15
|
作者
Blumel, Markus [1 ]
Liu, Jing [2 ]
de Jong, Isabella [3 ]
Weiser, Sarah [4 ]
Fast, Jonas [5 ]
Litowski, Jennifer [6 ]
Shuman, Melissa [7 ]
Mehta, Shyam B. [8 ]
Amery, Leanne [9 ]
Tan, David Cheng Thiam [10 ]
Jia, Feng [11 ]
Shekhawat, Dushyant [12 ]
Dagallier, Camille [13 ]
Emamzadeh, Mina [9 ]
Medina, Annette [14 ]
Santos, Camilla [15 ]
Gasser, Florian [16 ]
Urban, Christian [17 ]
机构
[1] Novartis Pharm AG, Biol Analyt Dev, Lichtstr 35, CH-4056 Basel, Switzerland
[2] Seagen Inc, Pharmaceut Sci, 21717 30th Dr SE,Bldg 3, Bothell, WA 98021 USA
[3] Genentech Inc, Pharmaceut Dev, 1 DNA Way, South San Francisco, CA 94080 USA
[4] Pfizer Biotherapeut Pharmaceut Sci, 1 Burtt Rd, Andover, MA 01810 USA
[5] Hoffmann La Roche Ltd, Pharmaceut Dev & Supplies, PTD Biol Europe, Grenzacherstr 124, CH-4070 Basel, Switzerland
[6] Amgen Inc, Proc Dev, 360 Binney St, Cambridge, MA 02141 USA
[7] GSK, Strateg External Dev, Sterile Drug Prod Operat, 1250 S Collegeville Rd, Collegeville, PA 19426 USA
[8] Teva Branded Pharmaceut Prod R&D Inc, Drug Metab & Pharmacokinet, 145 Brandywine Pkwy, W Chester, PA 19380 USA
[9] AstraZeneca, Dosage Form Design & Dev, Aaron Klug Bldg,Granta Pk, Cambridge CB21 6GH, Cambs, England
[10] AbbVie Inc, N Chicago, IL USA
[11] Biogen Biol Drug Prod, Cambridge, MA 02142 USA
[12] Eli Lilly & Co, Bioprod Res & Dev, Indianapolis, IN 46285 USA
[13] Sanofi, Biol Drug Prod Dev, 1 Impasse Ateliers, F-94403 Vitry Sur Seine, France
[14] AstraZeneca, Dosage Form Design & Dev, One Medimmune Way, Gaithersburg, MD 20878 USA
[15] Amgen Inc, Prod Qual, 40 Technol Way, West Greenwich, RI 02817 USA
[16] Novartis Pharm AG, Biol Analyt Dev, Biochemiestr 10, A-6336 Langkampfen, Austria
[17] Sanofi, Biol Drug Prod Dev, Industriepark Hochst, D-65926 Frankfurt, Germany
关键词
Protein delivery; Analytical chemistry; Polymeric drug delivery system(s); Regulatory science; MONOCLONAL-ANTIBODIES; PROTEIN FORMULATIONS; TRANSFER DEVICES; INFUSION BAGS; LINE FILTERS; STORAGE; DRUG; PERSPECTIVE; PARTICLES; GLYCATION;
D O I
10.1016/j.xphs.2023.05.002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.& COPY; 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2332 / 2346
页数:15
相关论文
共 50 条
  • [21] Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials
    Arnamo, A. Hedvig
    Pluim, Dick
    Huitema, Alwin D. R.
    Jacobs, Bart A. W.
    Beijnen, Jos H.
    Nuijen, Bastiaan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [22] Design of a Reciprocal Injection Device for Stability Studies of Parenteral Biological Drug Products
    Du, Yong
    Song, Jing
    Lu, Lynn
    Yeung, Edward
    Givand, Jeffrey
    Procopio, Adam
    Su, Yongchao
    Hu, Guangli
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (05) : 1330 - 1338
  • [23] Individual adaptation of industry LCA practice: Results from two case studies in the Swedish forest products industry
    Emma L. C. Rex
    Henrikke Baumann
    The International Journal of Life Cycle Assessment, 2007, 12 : 266 - 271
  • [24] Individual adaptation of industry LCA practice: Results from two case studies in the Swedish forest products industry
    Rex, Emma L. C.
    Baumann, Henrikke
    INTERNATIONAL JOURNAL OF LIFE CYCLE ASSESSMENT, 2007, 12 (04): : 266 - 271
  • [25] In-use stability assessment of FDA approved metformin immediate release and extended release products for N-Nitrosodimethylamine and dissolution quality attributes
    Dharani, Sathish
    Mohamed, Eman M.
    Khuroo, Tahir
    Ali, Hamed I.
    Reddy, Indra K.
    Rahman, Ziyaur
    Khan, Mansoor A.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 623
  • [26] HANDBOOK OF FACTORY DESIGN - DETAILS - BEST OF CURRENT PRACTICE - SECTION 7 - CASE STUDIES 2
    CLARKE, C
    WINTER, J
    ARCHITECTS JOURNAL, 1979, 170 (33): : 347 - 353
  • [27] Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions
    Park, Dongkuk
    Kim, Jihyun
    Yun, Jihoon
    Park, Su Jin
    ADVANCES IN THERAPY, 2020, 37 (10) : 4308 - 4324
  • [28] 'Use of current best evidence': Promises and illusions, limitations and contradictions in the triangle of research, policy and practice
    Lassnigg, Lorenz
    INTERNATIONAL JOURNAL OF TRAINING RESEARCH, 2012, 10 (03): : 179 - 203
  • [30] Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions
    Dongkuk Park
    Jihyun Kim
    Jihoon Yun
    Su Jin Park
    Advances in Therapy, 2020, 37 : 4308 - 4324